Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
This is a multicenter study assessing the efficacy of different therapeutic strategy in patients with advanced sarcomas.
Sarcoma
DRUG: Combination of MK3475 with Metronomic CP|DRUG: Combination of MK3475 with Metronomic CP and G100
Assessment of the efficacy of MK3475 associated with Metronomic Cyclophosphamide per RECIST v1.1 criteria, This primary objective of this study is to assess the efficacy of MK3475 and Metronomic Cyclophosphamide (CP) independently for 6 strata as per RECIST v1.1 criteria :

In terms of 6-month objective response and 6-months non progression for:

* Advanced leiomyosarcoma
* Advanced undifferentiated sarcoma
* Advanced other sarcoma
* Advanced osteosarcoma

In terms of·6-month non progression for:

* Advanced GIST
* Advanced soft-tissue sarcoma with immune signature, 6 months|Assessment of the efficacy of MK3475 associated with Metronomic Cyclophosphamide and G100 per RECIST v1.1 criteria, This primary objective of this study is to assess the efficacy of MK3475 and Metronomic Cyclophosphamide (CP) and G100 as per RECIST v1.1 criteria, in terms of 6-months non progression for metastatic soft-tissue sarcoma., 6 months
Efficacy of the treatment strategy in terms of Best overall response, Assessment of the efficacy of the treatment strategy in terms of best overall response (as per RECIST v1.1 criteria), participants will be followed for the duration of treatment, an expected average of 6-months|Efficacy of the treatment strategy in terms of Progression-free Survival, Assessment of the efficacy of the treatment strategy in terms of 1-year progression-free survival (as per RECIST v1.1 criteria), Progression-free survival assessed at 12 months|Efficacy of the treatment strategy in terms of Immune_related Response, Assessment of the efficacy of the treatment strategy in terms of 6-months immune-related response (as per Wolchok 2009), Immune-related response assessed at 6 months|Efficacy of the treatment strategy in terms of Overall Survival., Assessment of the efficacy of the treatment strategy in terms of 1-year overall survival, Overall survival assessed at 12 months|Safety profile of the treatment strategy.Toxicity graded using the Common Terminology Criteria for Adverse Events version 4, Toxicity graded using the Common Terminology Criteria for Adverse Events version 4, Throughout the treatment period, an average of 6 months|Exploration of blood cytokines levels (TNFγ, TNFα, TGFβ, IL2, 4, 6, 10) (ELISA), Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression|Exploration of blood VEGF, Svegfr2 and TPS-1 levels (ELISA), Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression|Exploration of lymphocytes subpopulations monitoring, CD8+/Treg ratio (flow cytometry), Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression|Exploration of Plasma levels of Kynurenine and Kynurenine to Tryptophan ratio (ELISA and LC/MS), Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression
This is a phase 2 trial with 7 strata :

* Leiomyosarcoma (strata 1) : 33 patients
* Undifferentiated sarcoma (strata 2): 33 patients
* Sarcomas others (strata 3) : 33 patients
* Osteosarcoma (strata 4) : 33 patients
* GIST (strata 5): 31 patients
* Advanced soft-tissue sarcoma with immune signature (strata 6): 32 patients
* Metastatic soft-tissue sarcoma (strata 7): 32 patients